On March 26, 2026, DBV Technologies S.A. announced its financial results for the fiscal year ended December 31, 2025. The company reported an operating income of $5.6 million, an increase from $4.2 million in the previous year, driven by higher eligible activities related to the French Research Tax Credit. However, the net loss for the year was $147 million, compared to $113.9 million in 2024, reflecting increased research and development expenses as the company prepares for the potential commercialization of its VIASKIN Peanut Patch. DBV Technologies has bolstered its executive leadership team in anticipation of a Biologics License Application (BLA) submission and potential approval for its peanut allergy treatment. The company reported cash and cash equivalents of $194 million as of December 31, 2025, which, along with additional gross proceeds of $94 million received in January 2026, is expected to fund operations into the second quarter of 2027. The company is focused on advancing its clinical development programs and has reported positive topline results from the Phase 3 VITESSE trial for peanut-allergic children aged 4 to 7 years. DBV Technologies is committed to transforming the care of food allergic individuals and is actively engaging with the allergy and immunology communities to further its mission.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.